搜索优化
English
全部
搜索
图片
视频
地图
资讯
Copilot
更多
购物
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
最新
最佳匹配
资讯
2 小时
Stifel 重申 Apogee Therapeutics 股票买入评级,看好特应性皮炎数据
Investing.com - Stifel 在 Apogee Therapeutics Inc (NASDAQ: APGE) 近期发布的特应性皮炎 (AD)治疗药物 APG777 的 2a 期数据后,重申了其买入评级和 95.00 美元的目标价。根据 InvestingPro 数据,分析师目标价在 78 美元至 116 美元之间,整体共识为强烈买入推荐。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Central Texas flash floods
Trump admin sues California
Ex-doctor refuses to answer
Bitcoin hits record high
Barbie with Type 1 diabetes
Tunnel collapses in LA
Hiker dies in Grand Canyon
Ex-Jazz coach, GM dies
To release web browser
Cyclist LeMond honored
Won't revive immigration law
Copper tariffs to begin Aug 1
5-yr extension w/ Thunder
Loan interest to restart
X CEO resigns
US sanctions UN official
Confirmed to lead FAA
Cracker sandwiches recalled
Suffers serious injuries
Los Angeles joins ACLU suit
Six agents suspended
Sinner defeats Shelton
Malaysia’s ex-PM turns 100
14th Wimbledon semifinal
Utah judge sets execution
Harvard faces subpoenas
Makes first visit to Asia
Cases hit highest level
Death ruled a homicide
Former Gov. DiPrete dies
Booker gets max extension
Interim NASA administrator
Greece blocks asylum claims
Sentenced to 8+ years
反馈